A detailed history of J. Goldman & CO LP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 8,279 shares of AXSM stock, worth $751,153. This represents 0.02% of its overall portfolio holdings.

Number of Shares
8,279
Previous 8,336 0.68%
Holding current value
$751,153
Previous $671,000 10.73%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$78.93 - $95.84 $4,499 - $5,462
-57 Reduced 0.68%
8,279 $743,000
Q2 2024

Aug 14, 2024

SELL
$65.72 - $80.5 $36,803 - $45,080
-560 Reduced 6.29%
8,336 $671,000
Q1 2024

May 15, 2024

BUY
$69.39 - $97.64 $231,831 - $326,215
3,341 Added 60.14%
8,896 $709,000
Q4 2023

Feb 14, 2024

SELL
$57.42 - $83.61 $2.77 Million - $4.03 Million
-48,256 Reduced 89.68%
5,555 $442,000
Q3 2023

Nov 14, 2023

BUY
$69.25 - $82.21 $2.62 Million - $3.11 Million
37,865 Added 237.46%
53,811 $3.76 Million
Q2 2023

Aug 14, 2023

SELL
$58.41 - $90.35 $2.71 Million - $4.19 Million
-46,405 Reduced 74.43%
15,946 $1.15 Million
Q1 2023

May 15, 2023

BUY
$58.39 - $75.0 $3.48 Million - $4.47 Million
59,652 Added 2210.15%
62,351 $3.85 Million
Q4 2022

Feb 14, 2023

BUY
$39.94 - $79.72 $107,798 - $215,164
2,699 New
2,699 $208,000
Q1 2020

May 15, 2020

SELL
$41.2 - $101.31 $154,623 - $380,216
-3,753 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$16.71 - $106.24 $127,397 - $809,973
-7,624 Reduced 67.01%
3,753 $388,000
Q3 2019

Nov 14, 2019

BUY
$20.24 - $29.16 $34,387 - $49,542
1,699 Added 17.56%
11,377 $230,000
Q2 2019

Aug 14, 2019

SELL
$13.46 - $25.75 $501,990 - $960,346
-37,295 Reduced 79.4%
9,678 $249,000
Q1 2019

May 14, 2019

BUY
$2.63 - $16.34 $123,538 - $767,538
46,973 New
46,973 $668,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.89B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.